172 related articles for article (PubMed ID: 12040480)
1. Hemophagocytic syndrome: a rare complication of allogeneic nonmyeloablative hematopoietic stem cell transplantation.
Abe Y; Choi I; Hara K; Matsushima T; Nishimura J; Inaba S; Nawata H; Muta K
Bone Marrow Transplant; 2002 May; 29(9):799-801. PubMed ID: 12040480
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. Successful engraftment and stable full donor chimerism after myeloablation with thiotepa, fludarabine, and melphalan and CD34-selected peripheral allogeneic stem cell transplantation in hemophagocytic lymphohistiocytosis.
Cesaro S; Gazzola MV; Marson P; Calore E; Caenazzo L; Destro R; De Silvestro G; Varotto S; Pillon M; Zanesco L; Messina C
Am J Hematol; 2003 Feb; 72(2):143-6. PubMed ID: 12555220
[TBL] [Abstract][Full Text] [Related]
4. Early onset of hemophagocytic syndrome following allogeneic bone marrow transplantation.
Ishikawa J; Maeda T; Miyazaki T; Manabe N; Honda S; Nishiura T; Tomiyama Y; Matsuzawa Y
Int J Hematol; 2000 Aug; 72(2):243-6. PubMed ID: 11039676
[TBL] [Abstract][Full Text] [Related]
5. High complete response rate after allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimens in advanced malignant lymphoma.
Tanimoto TE; Kusumi E; Hamaki T; Yuji K; Ueyama J; Miyakoshi S; Morinaga S; Kami M; Kanda Y; Ando T; Yoshihara S; Masuo S; Kim SW; Nakai K; Tobinai K; Tanosaki R; Mineishi S; Takaue Y; Muto Y
Bone Marrow Transplant; 2003 Jul; 32(2):131-7. PubMed ID: 12838276
[TBL] [Abstract][Full Text] [Related]
6. Early renal injury after nonmyeloablative allogeneic peripheral blood stem cell transplantation in patients with chronic myelocytic leukemia.
Liu H; Ding JH; Liu BC; Zhao G; Chen BA
Am J Nephrol; 2007; 27(4):336-41. PubMed ID: 17519537
[TBL] [Abstract][Full Text] [Related]
7. [The clinical research of nonmyeloablative allogeneic peripheral blood hematopoietic stem cells transplantation for hematological diseases].
Ai HS; Yu CL; Wang DH; Guo M; Qiao JH; Shi BF; Sun WJ; Zhang S; Sun QY; Yao B
Zhonghua Xue Ye Xue Za Zhi; 2003 Feb; 24(2):86-9. PubMed ID: 12697103
[TBL] [Abstract][Full Text] [Related]
8. Reduced intensity conditioning regimen followed by glycosylated G-CSF mobilized PBSCT in patients with solid tumors and malignant lymphomas.
Castagna L; Bertuzzi A; Nozza A; Siracusano L; Balzarotti M; Magagnoli M; Sarina B; Timofeeva I; Sinnone M; Grimoldi MG; Farè M; Santoro A
Bone Marrow Transplant; 2002 Aug; 30(4):207-14. PubMed ID: 12203136
[TBL] [Abstract][Full Text] [Related]
9. Low transplant-related mortality after second allogeneic peripheral blood stem cell transplant with reduced-intensity conditioning in adult patients who have failed a prior autologous transplant.
Martino R; Caballero MD; de la Serna J; Díez-Martín JL; Urbano-Ispízua A; Tomás JF; Odriozola J; León A; Canals C; San Miguel J; Sierra J
Bone Marrow Transplant; 2002 Jul; 30(2):63-8. PubMed ID: 12132043
[TBL] [Abstract][Full Text] [Related]
10. Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases.
Resnick IB; Shapira MY; Slavin S
Transpl Immunol; 2005 Aug; 14(3-4):207-19. PubMed ID: 15982565
[TBL] [Abstract][Full Text] [Related]
11. [Two brothers with familial hemophagocytic lymphohistiocytosis, treated by transplantation of stem cells from a single unrelated donor].
Kraal KC; Bredius RG; Lankester AC; Granzen B; Oudshoorn M; Egeler RM
Ned Tijdschr Geneeskd; 2002 Nov; 146(48):2309-12. PubMed ID: 12497761
[TBL] [Abstract][Full Text] [Related]
12. Donor stem cell infusion after non-myeloablative conditioning for tolerance induction to HLA mismatched adult living-donor liver graft.
Donckier V; Troisi R; Toungouz M; Colle I; Van Vlierberghe H; Jacquy C; Martiat P; Stordeur P; Zhou L; Boon N; Lambermont M; Schandené L; Van Laethem JL; Noens L; Gelin M; de Hemptinne B; Goldman M
Transpl Immunol; 2004; 13(2):139-46. PubMed ID: 15380544
[TBL] [Abstract][Full Text] [Related]
13. Immunosuppressive total lymphoid irradiation-based reconditioning regimens enable engraftment after graft rejection or graft failure in patients treated with allogeneic hematopoietic stem cell transplantation.
Heinzelmann F; Lang PJ; Ottinger H; Faul C; Bethge W; Handgretinger R; Bamberg M; Belka C
Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):523-8. PubMed ID: 17869449
[TBL] [Abstract][Full Text] [Related]
14. Disease- or therapy-related bone marrow damage cannot be overcome by changes in stem cell source or dose in allogeneic transplantation.
Novotny JR; Rosenthal C; Elmaagacli AH; Dürig J; Beelen DW; Dührsen U
Eur J Haematol; 2004 Jul; 73(1):1-9. PubMed ID: 15182331
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
16. Early recurrence of rheumatoid arthritis after nonmyeloablative allogeneic blood stem cell transplantation in a patient with multiple myeloma.
Tapprich C; Fenk R; Schneider P; Bernhardt A; Haas R; Kobbe G
Bone Marrow Transplant; 2003 Sep; 32(6):629-31. PubMed ID: 12953137
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment of advanced peripheral T-cell lymphoma with an angiocentric growth pattern complicated with hemophagocytic syndrome by high-dose chemotherapy and autologous peripheral blood stem cell transplantation.
Sato T; Kogawa K; Iyama S; Kobayashi D; Sato Y; Kuribayashi K; Takada K; Hagiwara S; Oku T; Takahashi S; Matsunaga T; Takahashi M; Terui T; Kato J; Niitsu Y
Ann Hematol; 2002 Dec; 81(12):739-43. PubMed ID: 12483373
[TBL] [Abstract][Full Text] [Related]
18. A comparison of T-, B- and NK-cell reconstitution following conventional or nonmyeloablative conditioning and transplantation with bone marrow or peripheral blood stem cells from human leucocyte antigen identical sibling donors.
Petersen SL; Ryder LP; Björk P; Madsen HO; Heilmann C; Jacobsen N; Sengeløv H; Vindeløv LL
Bone Marrow Transplant; 2003 Jul; 32(1):65-72. PubMed ID: 12815480
[TBL] [Abstract][Full Text] [Related]
19. Early and late neurological complications after reduced-intensity conditioning allogeneic stem cell transplantation.
Barba P; Piñana JL; Valcárcel D; Querol L; Martino R; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1439-46. PubMed ID: 19822304
[TBL] [Abstract][Full Text] [Related]
20. [Allogeneic peripheral blood stem cell transplantation for a hepatitis B virus carrier with Epstein-Barr virus associated with hemophagocytic syndrome].
Sakai R; Maruta A; Yamazaki E; Kamijo A; Taguchi J; Hyo R; Tanaka M; Fujimaki K; Nagao T; Yoshiba M; Ishigatsubo Y
Rinsho Ketsueki; 2004 May; 45(5):397-401. PubMed ID: 15199750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
